Knee ArthroscopyPhase 3CHLORODEXNCT07674576
Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy
A Phase 3 study testing Sodium Chloride 0.9%, Dexamethasone and Chloroprocaine Injection [Clorotekal] in people with Knee Arthroscopy, run by CMC Ambroise Paré at 1 site in France.
Trial summary
Chloroprocaine is a short-acting local anesthetic that allows rapid recovery and early ambulation but is currently recommended for procedures lasting 40 minutes or less. Dexamethasone is commonly used during anesthesia for the prevention of postoperative nausea and vomiting and has also been shown to prolong the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Knee Arthroscopy
- What is being tested?
- Sodium Chloride 0.9%, Dexamethasone and Chloroprocaine Injection [Clorotekal]
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteFrance
- Study dates
- 1 Sep 2026to 1 Sep 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Undergoing knee arthroscopy lasting ≤ 40 minutes requiring spinal anesthesia (diagnostic arthroscopy or meniscal surgery),
- Signed written informed consent form,
- Affiliation to a social security system,
- Negative pregnancy test on the day of procedure for non-menopausal patients.
Who cannot join
- Contraindications to spinal anesthesia with intrathecal chloroprocaine
- History of diabetes,
- Pre-existing peripheral neuropathy,
- American Society of Anesthesiologists (ASA) physical status IV,
- Contraindication to dexamethasone,
- Hypersensitivity of any drug used in this study,
Show all 16Show fewer
- Long-term oral corticosteroid therapy,
- Chronic opioid use,
- Chronic pain syndromes,
- Contraindications to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (Ketoprofen, Celecoxib)
- Need for a peripheral nerve block in addition to spinal anesthesia (e.g. knee ligamentoplasty),
- Mental or linguistic inability to understand the study,
- Patients under legal protection (guardianship, curatorship or safeguard of justice),
- Patients currently included or planning to be included in another interventional study,
- Pregnant or breastfeeding women,
- Women of childbearing potential not using effective contraception.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Clinique Drouot Rémusat
Paris, Île-de-France Region, 75016
Cyril QUEMENEUR, MD, 01 44 14 11 11, c.quemeneur@gmx.com
About this study
Official title: Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy: a Double-blind, Randomized, Controlled Trial
Chloroprocaine is a short-acting local anesthetic that allows rapid recovery and early ambulation but is currently recommended for procedures lasting 40 minutes or less.
Dexamethasone is commonly used during anesthesia for the prevention of postoperative nausea and vomiting and has also been shown to prolong the duration of analgesia and sensory block after regional anesthesia.
Read more
Dexamethasone may therefore extend the duration of chloroprocaine spinal anesthesia, potentially allowing its use for longer surgical procedures while maintaining the benefits of rapid postoperative recovery.
This study aims to evaluate whether intravenous dexamethasone can prolong the effects of spinal anesthesia performed with chloroprocaine in adults undergoing knee arthroscopy.
Read the detailed description
This is a monocenter, prospective, randomized (1:1 ratio), controlled, parallel-group, double-blind, phase III superiority trial assessing the efficacy and the safety of IV dexamethasone for prolonging sensory block in patients undergoing knee arthroscopy under spinal anesthesia with chloroprocaine.
Participants will be randomly allocated into two groups:
- Group CHLORO (control group): Patients will receive spinal anesthesia with chloroprocaine 40mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.
- Group CHLORODEX (experimental group): Patients will receive spinal anesthesia with chloroprocaine 40 mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of dexamethasone at a dose of 0.15 mg/Kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.
To ensure blinding, study infusions (saline or dexamethasone) will be prepared in identical 100 mL bags and labelled by a pharmacy staff member or an "outside protocol" healthcare professional (physician or nurse) not involved in patient care or assessment.
The infusion will start approximately 10-15 minutes before the spinal punction.
In the operating room, patients will receive standard perioperative care for spinal anesthesia, including placement of a peripheral intravenous line, supplemental low-flow oxygen therapy to maintain SpO₂ > 93%, continuous hemodynamic monitoring, and strict aseptic precautions. Analgesic premedication with paracetamol combined with either ketoprofen or celecoxib will be administered according to institutional practice.
Spinal anesthesia will be performed with the patient in a semi-sitting position via the L3-L4 or L4-L5 interspace using a 25G x 80mm Sprotte needle. After cerebrospinal fluid reflux, 40 mg of chloroprocaine without adjuvant will be injected intrathecally, and patients will then be positioned in the supine position for the procedure.
Knee arthroscopy will be performed according to standard surgical practice, without any modification of the surgical procedure for study purposes.
No additional sedation or analgesia will be administered during the procedure. In the event of failure of spinal anesthesia or early recovery of sensation, conversion to general anesthesia or deep sedation may be performed at the discretion of the anesthesiologist, depending on the clinical situation.
Postoperatively, multimodal analgesia will be initiated according to the institutional protocol, combining paracetamol, nefopam, and either ketoprofen or celecoxib, with morphine administered if necessary.
Sensory and motor blocks will be assessed every 5 minutes after spinal puncture until regression of two dermatomes and then every 10 minutes until recovery of four dermatomes and complete motor function (maximum until hospital discharge).
Motor block will be assessed using the Bromage score and sensory block will be assessed using the Pin Prick test and the cold test.
The primary objective of the study is to evaluate the efficacy of intravenous dexamethasone in prolonging sensory block following spinal anesthesia with chloroprocaine, as assessed by the time from intrathecal injection to regression of sensory block by two dermatomes from the highest level of sensory block achieved, as measured by the pin-prick test.
- Conditions
- Knee Arthroscopy
- Being tested
- Sodium Chloride 0.9%, Dexamethasone, Chloroprocaine Injection [Clorotekal]
- Keywords
- Knee arthroscopy, dexamethasone, chloroprocaine, spinal anesthesia, sensory block, motor block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sodium Chloride 0.9%Drug
IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes
DexamethasoneDrug
IV infusion of dexamethasone at a dose of 0.15 mg/kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes
Chloroprocaine Injection [Clorotekal]Drug
Spinal anesthesia with chloroprocaine 40 mg
| Study group | Role | What they receive |
|---|---|---|
| CHLORO | Placebo comparator | Normal saline solution IV infusion Receives: Drug: Sodium Chloride 0.9%; Drug: Chloroprocaine Injection [Clorotekal] |
| CHLORODEX | Experimental | Dexamethasone IV infusion Receives: Drug: Dexamethasone; Drug: Chloroprocaine Injection [Clorotekal] |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to regression of sensory block by two dermatomes (pin-prick test)
Time (in minutes) from the spinal puncture to the first assessment at which the sensory block has regressed by two dermatomes from the maximum (highest/most cephalad) dermatome level of sensory block achieved after the puncture, assessed with the pin-prick test. Sensory testing will be performed every 5 minutes until two-dermatome regression is observed. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.
Measured: Up to 2 hours following spinal anesthesia
Secondary outcomes (17)
Time to complete resolution of motor block
Time (in minutes) from the spinal puncture to complete recovery of motor block, assessed by the Modified Bromage Scale (0-3: 0 = full flexion of hip, knee, and ankle; 1 = inability to raise extended leg; 2 = inability to flex knee; 3 = no movement of hip, knee, or ankle). Motor block will be assessed every 5 minutes after the spinal puncture until regression of the sensory block by two dermatomes, and then every 10 minutes until complete motor recovery (Bromage 0).
Measured: Up to 8 hours following spinal anesthesia
Time to regression of sensory block by four dermatomes (pin-prick test)
Time (in minutes) from the spinal puncture to regression of four dermatomes from the highest dermatome level of sensory block achieved after the puncture. Sensory block will be assessed using the pin-prick test every 5 minutes after the spinal puncture until regression by two dermatomes, and then every 10 minutes until regression by four dermatomes. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.
Measured: Up to 8 hours following spinal anesthesia
Maximum sensory block level
Highest dermatome level of sensory block achieved after the spinal puncture (pin-prick test).
Measured: Up to 30 minutes following spinal anesthesia
Time to maximum sensory block level
Time (in minutes) from the spinal puncture to the highest blocked dermatome (pin-prick test).
Measured: Up to 30 minutes following spinal anesthesia
Need for additional anesthetic procedure
Whether an additional anesthetic procedure was required during surgery, including sedation or conversion to general anesthesia
Measured: From spinal anesthesia to the end of surgery
Time to regression of sensory block by two dermatomes (cold test)
Time (in minutes) from spinal puncture to two dermatome sensory regression assessed by a standardized cold test
Measured: Up to 2 hours following spinal anesthesia
Incidence of hypotension
Any episode of hypotension, defined as a systolic blood pressure (SBP) < 90 mmHg and/or a mean arterial pressure (MAP) < 65 mmHg and/or a decrease in blood pressure ≥ 30% from baseline
Measured: From spinal anesthesia to 24 hours after surgery
Incidence of bradycardia
Any episode of bradycardia defined as a heart rate (HR) < 50 bpm
Measured: From spinal anesthesia to 24 hours after surgery
Incidence of nausea
Any episode of nausea reported by the patient or nursing team
Measured: From spinal anesthesia to 24 hours after surgery
Incidence of vomiting
Any episode of vomiting reported by the patient or nursing team
Measured: From spinal anesthesia to 24 hours after surgery
Incidence of pruritus
Any episode of pruritus reported by the patient or nursing team
Measured: From spinal anesthesia to 24 hours after surgery
Incidence of urinary retention
Any episode of urinary retention reported by the patient or nursing team
Measured: From spinal anesthesia to 24 hours after surgery
Maximal pain score in the PACU
Maximal pain score collected in the PACU using a Numeric Rating Scale (NRS-Pain) ranging from 0 to 10 (0= no pain; 10= extreme pain).
Measured: Up to 6 hours following spinal anesthesia
Total opioid consumption
Total opioid consumption, converted to oral morphine equivalents (OME, mg) from the intraoperative period to 24 hours postoperatively, including opioid use at home as reported during the Day 1 follow-up
Measured: From spinal anesthesia to 24 hours after surgery
Pain intensity
Pain intensity at rest and during movement will be assessed using a Numeric Rating Scale (NRS-Pain) ranging from 0 to 10 (0= no pain; 10= extreme pain). Pain scores will be recorded intraoperatively (H0)in the PACU (H1), during ambulatory hospitalization (H3 and H6), and at home until Day-1 (H9, H12 and H24).
Measured: From spinal anesthesia to 24 hours after surgery
Duration of surgery
Time (in minutes) between the skin incision and the last suture
Measured: Intraoperative period
Incidence of post-puncture headache
Any episode of headache reported by the patient or nursing team
Measured: From spinal anesthesia to 24 hours after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2026
- Study start1 Sep 2026 (estimated)
- Primary completion31 Aug 2028 (estimated)
- Study completion1 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Knee ArthroscopyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CMC Ambroise Paré
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07674576
- Sponsor's protocol ID
- 2023/01
- Other IDs
- 2023-505247-39-00, 2023
- Acronym
- CHLORODEX
- Status last verified
- Jun 2026
- First submitted
- 19 Jun 2026
- Last updated
- 29 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy: a Double-blind, Randomized, Controlled Trial
- ClinicalTrials.gov ID
- NCT07674576
- Acronym / sponsor ID
- CHLORODEX / 2023/01
- Conditions
- Knee Arthroscopy
- Keywords
- Knee arthroscopy, dexamethasone, chloroprocaine, spinal anesthesia, sensory block, motor block
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- CMC Ambroise ParéUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 31 Aug 2028 (estimated)
- Study completion
- 1 Sep 2028 (estimated)
- First posted
- 29 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chloroprocaine is a short-acting local anesthetic that allows rapid recovery and early ambulation but is currently recommended for procedures lasting 40 minutes or less.
Dexamethasone is commonly used during anesthesia for the prevention of postoperative nausea and vomiting and has also been shown to prolong the duration of analgesia and sensory block after regional anesthesia.
Dexamethasone may therefore extend the duration of chloroprocaine spinal anesthesia, potentially allowing its use for longer surgical procedures while maintaining the benefits of rapid postoperative recovery.
This study aims to evaluate whether intravenous dexamethasone can prolong the effects of spinal anesthesia performed with chloroprocaine in adults undergoing knee arthroscopy.
Detailed description
This is a monocenter, prospective, randomized (1:1 ratio), controlled, parallel-group, double-blind, phase III superiority trial assessing the efficacy and the safety of IV dexamethasone for prolonging sensory block in patients undergoing knee arthroscopy under spinal anesthesia with chloroprocaine.
Participants will be randomly allocated into two groups:
- Group CHLORO (control group): Patients will receive spinal anesthesia with chloroprocaine 40mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.
- Group CHLORODEX (experimental group): Patients will receive spinal anesthesia with chloroprocaine 40 mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of dexamethasone at a dose of 0.15 mg/Kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.
To ensure blinding, study infusions (saline or dexamethasone) will be prepared in identical 100 mL bags and labelled by a pharmacy staff member or an "outside protocol" healthcare professional (physician or nurse) not involved in patient care or assessment.
The infusion will start approximately 10-15 minutes before the spinal punction.
In the operating room, patients will receive standard perioperative care for spinal anesthesia, including placement of a peripheral intravenous line, supplemental low-flow oxygen therapy to maintain SpO₂ > 93%, continuous hemodynamic monitoring, and strict aseptic precautions. Analgesic premedication with paracetamol combined with either ketoprofen or celecoxib will be administered according to institutional practice.
Spinal anesthesia will be performed with the patient in a semi-sitting position via the L3-L4 or L4-L5 interspace using a 25G x 80mm Sprotte needle. After cerebrospinal fluid reflux, 40 mg of chloroprocaine without adjuvant will be injected intrathecally, and patients will then be positioned in the supine position for the procedure.
Knee arthroscopy will be performed according to standard surgical practice, without any modification of the surgical procedure for study purposes.
No additional sedation or analgesia will be administered during the procedure. In the event of failure of spinal anesthesia or early recovery of sensation, conversion to general anesthesia or deep sedation may be performed at the discretion of the anesthesiologist, depending on the clinical situation.
Postoperatively, multimodal analgesia will be initiated according to the institutional protocol, combining paracetamol, nefopam, and either ketoprofen or celecoxib, with morphine administered if necessary.
Sensory and motor blocks will be assessed every 5 minutes after spinal puncture until regression of two dermatomes and then every 10 minutes until recovery of four dermatomes and complete motor function (maximum until hospital discharge).
Motor block will be assessed using the Bromage score and sensory block will be assessed using the Pin Prick test and the cold test.
The primary objective of the study is to evaluate the efficacy of intravenous dexamethasone in prolonging sensory block following spinal anesthesia with chloroprocaine, as assessed by the time from intrathecal injection to regression of sensory block by two dermatomes from the highest level of sensory block achieved, as measured by the pin-prick test.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CHLORO | Placebo comparator | Drug: Sodium Chloride 0.9%, Drug: Chloroprocaine Injection [Clorotekal]Normal saline solution IV infusion |
| CHLORODEX | Experimental | Drug: Dexamethasone, Drug: Chloroprocaine Injection [Clorotekal]Dexamethasone IV infusion |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Undergoing knee arthroscopy lasting ≤ 40 minutes requiring spinal anesthesia (diagnostic arthroscopy or meniscal surgery),
- Signed written informed consent form,
- Affiliation to a social security system,
- Negative pregnancy test on the day of procedure for non-menopausal patients.
Key exclusion criteria (16 listed)
- Contraindications to spinal anesthesia with intrathecal chloroprocaine
- History of diabetes,
- Pre-existing peripheral neuropathy,
- American Society of Anesthesiologists (ASA) physical status IV,
- Contraindication to dexamethasone,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sodium Chloride 0.9%IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes | Drug | CHLORO |
| DexamethasoneIV infusion of dexamethasone at a dose of 0.15 mg/kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes | Drug | CHLORODEX |
| Chloroprocaine Injection [Clorotekal]Spinal anesthesia with chloroprocaine 40 mg | Drug | CHLORO, CHLORODEX |
Primary outcome
Time to regression of sensory block by two dermatomes (pin-prick test)
Time frame: Up to 2 hours following spinal anesthesia
Time (in minutes) from the spinal puncture to the first assessment at which the sensory block has regressed by two dermatomes from the maximum (highest/most cephalad) dermatome level of sensory block achieved after the puncture, assessed with the pin-prick test. Sensory testing will be performed every 5 minutes until two-dermatome regression is observed. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.
17 secondary outcomes
Time to complete resolution of motor block
Time frame: Up to 8 hours following spinal anesthesia
Time to regression of sensory block by four dermatomes (pin-prick test)
Time frame: Up to 8 hours following spinal anesthesia
Maximum sensory block level
Time frame: Up to 30 minutes following spinal anesthesia
Time to maximum sensory block level
Time frame: Up to 30 minutes following spinal anesthesia
Need for additional anesthetic procedure
Time frame: From spinal anesthesia to the end of surgery
Time to regression of sensory block by two dermatomes (cold test)
Time frame: Up to 2 hours following spinal anesthesia
Incidence of hypotension
Time frame: From spinal anesthesia to 24 hours after surgery
Incidence of bradycardia
Time frame: From spinal anesthesia to 24 hours after surgery
Incidence of nausea
Time frame: From spinal anesthesia to 24 hours after surgery
Incidence of vomiting
Time frame: From spinal anesthesia to 24 hours after surgery
Incidence of pruritus
Time frame: From spinal anesthesia to 24 hours after surgery
Incidence of urinary retention
Time frame: From spinal anesthesia to 24 hours after surgery
Maximal pain score in the PACU
Time frame: Up to 6 hours following spinal anesthesia
Total opioid consumption
Time frame: From spinal anesthesia to 24 hours after surgery
Pain intensity
Time frame: From spinal anesthesia to 24 hours after surgery
Duration of surgery
Time frame: Intraoperative period
Incidence of post-puncture headache
Time frame: From spinal anesthesia to 24 hours after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Knee Arthroscopy
Recruiting
Anterior Nerves of the Knee Block Versus Femoral Nerve Block for Knee Arthroscopy
Postoperative Pain, Knee Arthroscopy
Not yet recruiting
Clinical and Biological Outcomes of BioBrace-Augmented ACL Reconstruction
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture
Not yet recruitingPhase 4
Geko™ Device in Prevention of Pain and Swelling Following Knee Arthroscopy
Post Operative Swelling
Active, not recruitingPhase 3
Dronabinol After Arthroscopic Surgery
Knee Osteoarthritis, Knee Injuries
Not yet recruiting
Needle Arthroscopy vs Conventional Arthroscopy in Knees
Meniscectomy, Meniscal Tears
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Sodium Chloride 0.9%, Dexamethasone and Chloroprocaine Injection [Clorotekal] in people with Knee Arthroscopy, run by CMC Ambroise Paré at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sébastien BLOC, MD (01 44 14 11 11, sebebloc@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to regression of sensory block by two dermatomes (pin-prick test) (time frame: Up to 2 hours following spinal anesthesia). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.